Discussion in 'Fibromyalgia Main Forum' started by ulala, Sep 25, 2009.
[This Message was Edited on 09/25/2009]
xmrv may be related to CFS. A treatment may be rituxan.
Clinical impact of B-cell depletion with the anti-CD20 antibody rituximab in chronic fatigue syndrome: a preliminary case series.Fluge Ø, Mella O.
Department of Oncology and Medical Physics, Haukeland University Hospital, N-5021 Bergen, Norway. email@example.com
BACKGROUND: Chronic fatigue syndrome (CFS) is a disease of unknown aetiology. A patient with CFS had unexpected, marked recovery of CFS symptoms lasting for five months during and after cytotoxic chemotherapy for Hodgkin's disease. We reasoned that the transient CFS recovery was related to methotrexate treatment, which induces immunomodulation in part through B-cell depletion. METHODS: In a case series, this patient and two additional CFS patients were B-cell depleted by infusion of the monoclonal anti-CD20 antibody rituximab. RESULTS: All three had improvement of all CFS symptoms. Patients 1 and 2 had major amelioration from 6 weeks after intervention, patient 3 slight improvement from the same time, but then improved markedly from 26 weeks after intervention. The symptomatic effect lasted until weeks 16, 18 and 44, respectively. At relapse, all were retreated with a single (patient 1) or double rituximab infusion (patients 2 and 3). Again, all three had marked symptom improvement, mimicking their first response. After new symptom recurrence, patients 1 and 2 were given weekly oral methotrexate, patient 1 having effect also from this agent. Patients 1 and 2 were again treated for a third rituximab infusion after new relapse, again with a marked clinical benefit. No unexpected toxicity was seen. CONCLUSION: These observations suggest that B-lymphocytes are involved in CFS pathogenesis for a subset of patients. Benefit for all CFS symptoms, the delayed symptom relief following B-cell depletion, the kinetics of relapses, and the effect also from methotrexate treatment, provide suggestive evidence that B-cells play a significant role in the ongoing clinical features, and that CFS may be amenable to therapeutic interventions aimed at modifying B-cell number and function. More systematic investigations of this therapeutic strategy, and of its biological basis, are now needed.
PMID: 19566965 [PubMed - indexed for MEDLINE]
ReviewRituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. Drugs. 2003; 63(8):803-43.
Efficacy of anti-CD20 treatment in patients with rheumatoid arthritis resistant to a combination of methotrexate/anti-TNF therapy. Scand J Immunol. 2007 Oct; 66(4):476-83.
[Scand J Immunol. 2007]
B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med. 2008 Feb 14; 358(7):676-88.
[N Engl J Med. 2008]
Long-term observation of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis treated with rituximab. Rheumatology (Oxford). 2006 Nov; 45(11):1432-6. Epub 2006 Apr 21.
[Rheumatology (Oxford). 2006]
ReviewTargeting B cells in SLE: the experience with rituximab treatment (anti-CD20). Endocr Metab Immune Disord Drug Targets. 2006 Dec; 6(4):345-50.
[Endocr Metab Immune Disord Drug Targets. 2006]
» See reviews... | » See all...
Patient Drug Information
Methotrexate (Rheumatrex®, Trexall®) Methotrexate is used to treat severe psoriasis (a skin disease in which red, scaly patches form on some areas of the body) that cannot be controlled by other treatments. Methotrexate is also used along with rest, physica...
Source: AHFS Consumer Medication Information
Recent Activity Clear Turn Off Turn On
Clinical impact of B-cell depletion with the anti-CD20 antibody rituximab in chronic fatig...Clinical impact of B-cell depletion with the anti-CD20 antibody rituximab in chronic fatigue syndrome: a preliminary case series.Your browsing activity is empty.
[This Message was Edited on 09/25/2009]
Separate names with a comma.